Search Results 1891-1900 of 18099 for Multiple system atrophy

  1. Neurosurgery - Clinical trials

    ... multiple myeloma. Also eligible are (11) up to 6 donors with triple negative breast cancer and (12) up to 6 donors with colorectal cancer who have no ...

  2. Neurosurgery - Clinical trials

    ... multiple myeloma. Also eligible are (11) up to 6 donors with triple negative breast cancer and (12) up to 6 donors with colorectal cancer who have no ...

  3. Neurosurgery - Clinical trials

    ... multiple myeloma. Also eligible are (11) up to 6 donors with triple negative breast cancer and (12) up to 6 donors with colorectal cancer who have no ...

  4. Neurosurgery - Clinical trials

    ... multiple myeloma. Also eligible are (11) up to 6 donors with triple negative breast cancer and (12) up to 6 donors with colorectal cancer who have no ...

  5. Neurosurgery - Clinical trials

    ... multiple myeloma. Also eligible are (11) up to 6 donors with triple negative breast cancer and (12) up to 6 donors with colorectal cancer who have no ...

  6. Neurosurgery - Clinical trials

    ... multiple myeloma. Also eligible are (11) up to 6 donors with triple negative breast cancer and (12) up to 6 donors with colorectal cancer who have no ...

  7. Transverse myelitis - Doctors and departments - Mayo Clinic

    D. Neurologist. Rochester, MN. Areas of focus: Meningitis, Multiple ... system, Encephalitis, Demyelinating disease, Neurosarcoidosis, Progressive ...

  8. A Study to Understand Why Laying Down May Influence High Blood Pressure in Patient's with a Disease that Causes Problems with the Autonomic Nervous System - Mayo Clinic

    The purpose of this research study is to better understand why patients with a disease that causes problems with the autonomic nervous system often have high ...

  9. Study to Evaluate Imetelstat (JNJ-63935937) in Subjects With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) - Mayo Clinic

    Study to Evaluate Imetelstat (JNJ-63935937) in Subjects With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome ...

  10. My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors - Mayo Clinic

    ... system [IWRS] prior to initiation of treatment); Adequate hematologic, renal ... multiple myeloma; LVEF below institutional lower level of normal (LLN) ...